DiaMedica Therapeutics Inc

NASDAQ:DMAC   3:59:43 PM EDT
6.55
+0.08 (+1.24%)
Products

Diamedica Reports Successful Type B Meeting With FDA For Study Of DM199

Published: 12/10/2020 13:34 GMT
DiaMedica Therapeutics Inc (DMAC) - Diamedica Therapeutics Announces Successful Type B Meeting With FDA for the Study of Dm199 in Patients With Acute Ischemic Stroke.
Diamedica Therapeutics Inc - Plans to Submit an Ind Application With to FDA for a Phase 2/3 Study in Q1 of 2021.
Diamedica Therapeutics Inc - FDA Agreed With Diamedica's Proposals Regarding Key Elements of a Phase 2/3 Trial for Dm199 in Patients With Ais.
Diamedica Therapeutics - FDA Did Not Recommend Additional Studies in Preparation for Ind Submission, Initiation of Planned Phase 2/3 Trial.